← All organizations
Highest phase reached
Phase 3
First clinical trial
Aug 1, 2004First marketed drug
Oct 7, 2021First NDA
Oct 7, 2021Last known activity
Oct 7, 2021
Acquired by Amgen on Aug 4, 2022
Timeline
Drugs by trial phase (10 distinct, 18 trials)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (4 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Albuminuria
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Arthritis
- Arthritis, Rheumatoid
- Atypical Hemolytic Uremic Syndrome
- Azotemia
- Celiac Disease
- Crohn Disease
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Glomerulonephritis, IGA
- Glomerulosclerosis, Focal Segmental
- Hemolysis
- Hemolytic-Uremic Syndrome
- Hidradenitis
- Hidradenitis Suppurativa
- Kidney Diseases
- Nephrosis
- Nephrotic Syndrome
- Syndrome
- Vasculitis
Marketed drugs (1)
Recent trials (33)
- NCT03852472Study directorPhase 2Dec 28, 2018
- NCT03852472Lead sponsorPhase 2Dec 28, 2018
- NCT03703908Lead sponsorPhase 2Oct 1, 2018
- NCT03703908Study directorPhase 2Oct 1, 2018
- NCT03536754Lead sponsorPhase 2May 1, 2018
- NCT03536754Study directorPhase 2May 1, 2018
- NCT03301467Study directorPhase 2Sep 29, 2017
- NCT03301467Lead sponsorPhase 2Sep 29, 2017
- NCT02994927Lead sponsorPhase 3Dec 1, 2016
- NCT02994927Study directorPhase 3Dec 1, 2016
- NCT02464891CollaboratorPhase 2Jun 4, 2015
- NCT02345408Lead sponsorPhase 1Feb 1, 2015
- NCT02384317Lead sponsorPhase 2Feb 1, 2015
- NCT02384317Study directorPhase 2Feb 1, 2015
- NCT02222155Lead sponsorPhase 2Sep 1, 2014
Details
- Founded
- Mountain View, CA, US Jan 1, 1997
- First NDA
- Oct 7, 2021
- Last known activity
- Oct 7, 2021
Designations held
- Orphan drug